Mary Katherine Lawrence, MD
- Carteret Medical Group Member
- Primary Specialty: Endocrinology & Metabolism
Affiliations
American College of Endocrinologists-Fellow,
Certified-International Society of Bone Densitometry,
Medical Director, Broad Street Clinic,
Chief of Staff-Carteret General Hospital-2011,
Former Credentials Committee Chair,
Member-Physicians for Social Responsibility
Education
- Board Certification
- Endocrinology & Metabolism
- Internal Medicine-American Board of Internal Medicine
- Fellowship
- UNC-Chapel Hill
- Medical School
- George Washington University School of Medicine
- Residency
- Vanderbilt University Hospitals
Medical Interests
Research Interests:
As a principal investigator, Dr. Lawrence conducts clinical studies in promising new treatments for diabetes and associated conditions. Patients who participate in a clinical study can learn more about their disease and its treatment, contribute to medical knowledge, and take advantage of study-related visits and procedures at no cost.
Below is a list of some of the approved medications for which Dr. Lawrence has conducted studies.
- Afrezza® rapid-acting inhaled insulin
- Symlin® (pramlintide) for diabetic patients taking insulin
- Glyset® (miglitol) to control blood glucose levels in Type 2 diabetes
- Amaryl® (glimepiride) sulfonylurea for Type 2 diabetes
- Pravachol® (pravastatin) to lower cholesterol
- Januvia® (sitagliptin) for Type 2 diabetes
- Bydureon ER® (exenatide) weekly injection for Type 2 diabetes
- Farxiga® (dapagliflozin) for glycemic control in Type 2 diabetes
- Ozempic® (semaglutide) weekly injection in Type 2 diabetes
- Xolair® (omalizumab) for moderate to severe asthma
- AndroGel® testosterone replacement therapy
- PRINCIPAL INVESTIGATOR in all of the following:
- Inhaled Insulin in Type 1 Diabetics
- Renal Failure in Type 2 Diabetics
- Cantata-02, SGLT 2 Inhibitor
- GBBD, type 2 diabetes on insulin
- Target Diabetic neuropathy, aldose reductase
- Renal Insufficiency in Diabetes
- Milly, Asthma
- Drug Naive Type 2 Diabetes, SGLT inhibitor
- Toccato: Rimonabontin Diabetes
- E2008 Diabetic Neuropathy
- E2007 Diabetic Neuropathy
- Extra Xolair in Asthma
- DPP-4 in Drug Naive Diabetes
- CV-168 Drug Naive Type 2 Diabetes
- Ascend Diabetic Nephropathy
- Symlin in Type 1 and 2 Diabetes
- IDAS-Inhaled Insulin in Asthma/COPD
- IDAH-Inhaled Insulin in Type I DM
- IDAP-Inhaled Insulin in Type II DM
- DPP-4 Inhibitor in Diabetic Nephropathy
- TREAT Anemia in Diabetic Nephropathy
- Matrix Urinary Incontinence
- Domperodine Trial Diabetic Gastroparesis
- Trumpet-Hyperlipidemia
- Smart Study-Asthma
- Glimepiride in Type 2 Diabetes
- Miglitol in Type 2 Diabetes
- SUB-INVESTIGATOR
- Bisphosphonates in Osteoporosis
- Testosterone Replacement in Type 2 Diabetes
- Pravastatin in Hyperlipidemia
- Diabetes and Thyroid Disease
- Osteoporosis detection, prevention and treatment